|
1
|
Carbone M, Kratzke RA and Testa JR: The
pathogenesis of mesothelioma. Semin Oncol. 29:2–17. 2002.
View Article : Google Scholar
|
|
2
|
Nowak AK, Lake RA, Kindler HL and Robinson
BW: New approaches for mesothelioma: biologics, vaccines, gene
therapy, and other novel agents. Semin Oncol. 29:82–96. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tomek S, Emri S, Krejcy K and Manegold C:
Chemotherapy for malignant pleural mesothelioma: past results and
recent developments. Br J Cancer. 88:167–174. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Vogelzang NJ, Rusthoven JJ, Symanowski J,
et al: Phase III study of pemetrexed in combination with cisplatin
versus cisplatin alone in patients with malignant pleural
mesothelioma. J Clin Oncol. 21:2636–2644. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Takeuchi K and Ito F: Receptor tyrosine
kinases and targeted cancer therapeutics. Biol Pharm Bull.
34:1774–1780. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Benati D and Baldari CT: SRC family
kinases as potential therapeutic targets for malignancies and
immunological disorders. Curr Med Chem. 15:1154–1165. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sen B and Johnson FM: Regulation of Src
family kinases in human cancers. J Signal Transduct. 2011:1–14.
2011. View Article : Google Scholar
|
|
8
|
Thomas SM and Brugge JS: Cellular
functions regulated by Src family kinases. Annu Rev Cell Dev Biol.
13:513–609. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ishizawar R and Parsons SJ: C-Src and
cooperating partners in human cancer. Cancer Cell. 6:209–214. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Abram CL and Courteidge: Src family
tyrosine kinases and growth factor signaling. Exp Cell Res.
254:1–13. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Roche S and Courtneidge SA: v-Yes as a
transforming factor. Oncogenic Cytoplasmic Tyrosine Kinases. Peters
G and Vousden KH: Oxford University Press; Oxford; pp. 87–120.
1997
|
|
12
|
Pena SV, Melhem MF, Meisler AI and
Cartwright CA: Elevated c-Yes tyrosine kinase activity in
premalignant lesions of the colon. Gastroenterology. 108:117–124.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Han NM, Curley SA and Gallick GE:
Differential activation of pp60(c-src) and pp62(c-yes) in human
colorectal carcinoma liver metastases. Clin Cancer Res.
2:1397–1404. 1996.PubMed/NCBI
|
|
14
|
Kashiwagi K, Harada K, Yano Y, et al: A
redox-silent analogue of tocotrienol inhibits hypoxia adaptation of
lung cancer cells. Biochem Biophys Res Commun. 365:875–881. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tsao AS, He D, Saigal B, et al: Inhibition
of c-Src expression and activation in malignant pleural
mesothelioma tissues leads to apoptosis, cell cycle arrest, and
decreased migration and invasion. Mol Cancer Ther. 6:1962–1972.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sancier F, Dumont A, Sirvent A, et al:
Specific oncogenic activity of the Src-family tyrosine kinase c-Yes
in colon carcinoma cells. Plos One. 6:1–10. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kato-Stankiewicz J, Hakimi I, Zhi G, et
al: Inhibitors of Ras/Raf-1 interaction identified by two hybrid
screening revert Ras-dependent transformation phenotypes in human
cnacer cells. Proc Natl Acad Sci USA. 99:14398–14403. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kim YM, Ma H, Oehler VG, et al: The gamma
catenin/CBP complex maintains survivin transcription in β-catenin
deficient/depleted cancer cells. Curr Cancer Drug Targets.
11:213–225. 2011.PubMed/NCBI
|
|
19
|
Vogelzang NJ, Rusthoven JJ, Symanowski J,
et al: Phase III study of pemetrexed in combination with cisplatin
versus cisplatin alone in patients with malignant pleural
mesothelioma. J Clin Oncol. 15:493–500. 2003.PubMed/NCBI
|
|
20
|
Kao SC, Lee K, Armstrong NJ, et al:
Validation of tissue microarray technology in malignant pleural
mesothelioma. Pathology. 43:128–132. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Johnson FM, Saigal B, Tran H and Donato
NJ: Abrogation of signal transducer and activator of transcription
3 reactivation after Src kinase inhibition results in synergistic
antitumor effects. Clin Cancer Res. 13:4233–4244. 2007. View Article : Google Scholar
|
|
22
|
Menges CW, Chen Y, Mossman BT, et al: A
phosphotyrosine proteomic screen identifies multiple tyrosine
kinase signaling pathways aberrantly activated in malignant
mesothelioma. Genes Cancer. 1:493–505. 2010. View Article : Google Scholar
|
|
23
|
Kashiwagi K, Virgona N, Harada K, et al: A
redox-silent analogue of tocotrienol acts as a potential cytotoxic
agent against human mesothelioma cells. Life Sci. 84:650–656. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cadigan KM: TCFs and Wnt/β-catenin
signaling: more than one way to throw the switch. Curr Top Dev
Biol. 98:1–34. 2012.
|
|
25
|
Saini SS and Klein MA: Targeting cyclin D1
in non-small cell lung cancer and mesothelioma cells by antisense
oligonucleotides. Anticancer Res. 31:3683–3690. 2011.PubMed/NCBI
|
|
26
|
Oneyama C, Ichino T, Saito K, et al:
Transforming potential of Src family kinases is limited by the
cholesterol-enriched membrane microdomain. Mol Cell Biol.
29:6462–6472. 2009. View Article : Google Scholar : PubMed/NCBI
|
